Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype of non-Hodgkin lymphoma, where patients often become chemoresistant after responding to initial therapy.

Dr. Goy, an international expert in the field, led the lenalidomide global pivotal trial known as MCL-001 or EMERGE trial. Lenalidomide belongs to a category of immunomodulators that is first-in-class approved for lymphoma. This Phase II study showed that lenalidomide induced rapid and prolonged response in patients who were heavily pretreated regardless of the number of their prior regimens and with a median duration of response of more than 16 months. Many of these patients had also been refractory to their last prior therapy. The EMERGE trial results were published in the leading Journal of Clinical Oncology ("Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study" JCO September 2013).

"This trial led to the recent approval by the FDA of lenalidomide as the first oral compound available for that disease addressing a definite unmet need for these patients," said Andre Goy, M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "Lenalidomide is only the second drug ever approved for the treatment of mantle-cell lymphoma."

The second study was published in the New England Journal of Medicine a few weeks ago in collaboration
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... , ... Food and Drug Administration (FDA) has notified health professionals, and ... -- from the use of negative pressure wound therapy (NPWT). ... therapy devices can help in the healing and closure of ...
... , ... a leading provider of software solutions to optimize clinical ... release of StudyOptimizer 4, the latest iteration of its ... pharmaceutical companies, DecisionView,s flagship product now includes advanced historical ...
Cached Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna ... a global biopharmaceutical company focused on,endocrine therapy ... in the,safety study of the Company,s Phase ... (BPH)., Cetrorelix, a novel investigational luteinizing ...
... 14 /PRNewswire-FirstCall/,-- HeartWare Limited (ASX: HTW) today announced that ... Seventh Annual JMP Securities Research,Conference at 9:30 a.m. PT ... is being held at the Ritz-Carlton, San Francisco May ... at the conference will be,available via a link provided ...
... Johns Hopkins doctors has fine-tuned the dosage and timing ... with strokes caused by bleeding within the brain. The ... Conference in Nice, France, has been shown to dramatically ... lethal subset of stroke. , "We,ve gone from what,s ...
... self esteem, SAUSALITO, Calif., May 14 When Peggy ... afraid to go to school,because she had lost her hair ... of her custom-made hair pieces and invited her and her,mother ... -- and raised the money to pay for it., ...
... Revenue Increase and 45% Profit Growth, RIO DE JANEIRO, Brazil, May 13 ... in Brazil, announced today its consolidated,results for the first quarter 2008., ... 1st QUARTER 2008 Highlights, ... March, 33.3% above the same period last ...
... today signed three bills into law:, Senate Bill ... pharmacies, under the supervision of the State Board of,Pharmacy, ... Under the program, drugs may be returned to an ... their original packaging and the,drug expires no sooner than ...
Cached Medicine News:Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Teen Girl Loses Hair But Gains Support 2Health News:Amil Has Strong Growth With High Profitability 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... management of diabetes in order to maintain tight ... effective way to reduce or even prevent diabetes-related ... improving a diabetes patients quality of life, however, ... have been the guiding factors in the development ...
... by the CGMS System Gold can assist ... program based on detailed glycemic profiles. Its ... improve motivation and collaboration with patients.1, ... with all diabetes patients, it may be ...
... Biographer is intended for detecting trends and ... (aged 18 and older) and children/adolescents (aged ... supervise the use of the G2 Biographer ... intended to supplement, not replace, conventional blood ...
Medicine Products: